Robert Mattson Peters

Robert Mattson Peters

Auto-generated profile, based on publicly available information

Robert Mattson Peters

Washington University in St. Louis School of Medicine, St. Louis, MO, United States

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ASA. Som
A. Som
JGJ. Groenendyk
J. Groenendyk
TAT. An
T. An
KPK. Patel
K. Patel
RPR. Peters
R. Peters
WRW. R. Ross
W. R. Ross
Comorbidities and socioeconomic barriers often limit patient adherence and self-management with hemodialysis. Missed sessions, often associated with communication barriers, can result in emergency dialysis and avoidable hospitalizations. This proof of concept study explored using a novel digital-messaging platform, EpxDialysis, to improve patient-to-dialysis center communication via widely available text messaging and telephone technology. A randomized controlled trial was conducted through Washington University-affiliated hemodialysis centers involving ESRD patients with poor attendance, defined as missing 2–6 sessions over the preceding 12 weeks. A cross-over study design evaluated appointment adherence between intervention and control groups. Comparing nonadherence rates eight weeks prior to enrollment, median appointment adherence after using the system increased by 75%, and median number of unintended hospitalization days fell by 31%. A conservative cost-benefit analysis of EpxDialysis demonstrates a 1:36 savings ratio from appointment adherence. EpxDialysis is a low-risk, cost-effective, intervention for increasing hemodialysis adherence in high-risk patients, especially at centers caring for vulnerable and low-income patients.

3 June 2020 in Telemedicine and e-Health
Verified
Journal Article
Closed access
RXRan Xu
Ran Xu
MXMaggie Xing
Maggie Xing
KJKavon Javaherian
Kavon Javaherian
RPRobert Peters
Robert Peters
WRWill Ross
Will Ross
CBCarlos Bernal-Mizrachi
Carlos Bernal-Mizrachi
Background: We conducted a randomized controlled trial of EpxDiabetes, a novel digital health intervention as an adjunct therapy to reduce HbA 1c and fasting blood glucose (FBG) among patients with type 2 diabetes mellitus (T2DM). In addition, we examined the effect of social determinants of health on our system. Methods: Sixty-five ( n  = 65) patients were randomized at a primary care clinic. Self-reported FBG data were collected by EpxDiabetes automated phone calls or text messages. Only intervention group responses were shared with providers, facilitating follow-up and bidirectional communication. ΔHbA 1c and ΔFBG were analyzed after 6 months. Results: There was an absolute HbA 1c reduction of 0.69% in the intervention group (95% confidence interval [CI], −1.41 to 0.02) and an absolute reduction of 0.03% in the control group (95% CI, −0.88 to 0.82). For those with baseline HbA 1c >8%, HbA 1c decreased significantly by 1.17% in the intervention group (95% CI, −1.90 to −0.44), and decreased by 0.02% in the control group (95% CI, −0.99 to 0.94). FBG decreased in the intervention group by 21.6 mg/dL (95% CI, −37.56 to −5.639), and increased 13.0 mg/dL in the control group (95% CI, −47.67 to 73.69). Engagement (proportion responding to ≥25% of texts or calls over 4 weeks) was 58% for the intervention group (95% CI, 0.373–0.627) and 48% for the control group (95% CI, 0.296–0.621). Smoking, number of comorbidities, and response rate were significant predictors of ΔHbA 1c . Conclusions: EpxDiabetes helps to reduce HbA 1c in patients with uncontrolled T2DM and fosters patient–provider communication; it has definite merit as an adjunct therapy in diabetes management. Future work will focus on improving the acceptability of the system and implementation on a larger scale trial.

30 September 2018 in Journal of Telemedicine and Telecare
Verified
Journal Article
Closed access
ESEric Sink
Eric Sink
KPKunjan Patel
Kunjan Patel
JGJacob Groenendyk
Jacob Groenendyk
RPRobert Peters
Robert Peters
ASAvik Som
Avik Som
WRWill Ross
Will Ross
Owing to its capacity to perform remote assessments, telemedicine is rising as a new force in chronic obstructive pulmonary disease (COPD) management. We conducted an eight month randomised-controlled-trial to study the effect of an automated telemedicine intervention on patients’ time-to-hospitalisation. A total of 168 patients with a diagnosis of COPD in the past 24 months were enrolled to receive the intervention at a primary care clinic. The treatment group received daily phone messages from an automated system asking them to report if they were breathing better than, worse than, or the same as the day prior. Patients reported their breathing status by responding to the text message or call. If a patient reported breathing worse, an alert was sent directly to that patient’s provider within the clinic. The control group received the same daily phone messages as the treatment group. However, no proactive breathing alerts were ever generated to the provider for these subjects. The primary outcome was the subjects’ time-to-first-COPD-related hospitalisation following the start of messages. The treatment group’s time-to-hospitalisation was significantly different than the control group’s with a hazard ratio of 2.36 (95% confidence interval 1.02–5.45, p = 0.0443). The number needed-to-treat ratio was 8.62. Subject engagement consistently ranged between 60% and 75%. The treatment group received both proactive monitoring and follow-up care from the providers. Active monitoring with provider feedback enables the detection of exacerbation events early enough for subjects to avoid admissions. The use of non-smartphone interventions reduces barriers to care presented by more complicated and expensive technologies. This intervention represents a simple, innovative, and inexpensive tool for improved COPD management.

25 July 2017 in JMIR Diabetes
Verified
Journal Article
Open access
RPRobert Mattson Peters
Robert Mattson Peters
MLMatt Lui
Matt Lui
KPKunjan Patel
Kunjan Patel
LTLewis Tian
Lewis Tian
KJKavon Javaherian
Kavon Javaherian
CBCarlos Bernal-Mizrachi
Carlos Bernal-Mizrachi
Emerging Technologies, Medical Devices, Apps, Sensors, and Informatics to Help People with Diabetes

18 September 2017 in JMIR Formative Research
Verified
Journal Article
Open access
ASAvik Som
Avik Som
KPKunjan Patel
Kunjan Patel
ESEric Sink
Eric Sink
RPRobert Mattson Peters
Robert Mattson Peters
KJKavon Javaherian
Kavon Javaherian
WRWill Ross
Will Ross
Patient noncompliance with therapy, treatments, and appointments represents a significant barrier to improving health care delivery and reducing the cost of care. One method to improve therapeutic adherence is to improve feedback loops in getting clinically acute events and issues to the relevant clinical providers as necessary (ranging from detecting hypoglycemic events for patients with diabetes to notifying the provider when patients are out of medications). Patients often don't know which information should prompt a call to their physician and proactive checks by the clinics themselves can be very resource intensive. We hypothesized that a two-way SMS system combined with a platform web service for providers would enable both high patient engagement but also the ability to detect relevant clinical alerts. The objectives of this study are to develop a feasible two-way automated SMS/phone call + web service platform for patient-provider communication, and then study the feasibility and acceptability of the Epharmix platform. First, we report utilization rates over the course of the first 18 months of operation including total identified clinically significant events, and second, review results of patient user-satisfaction surveys for interventions for patients with diabetes, COPD, congestive heart failure, hypertension, surgical site infections, and breastfeeding difficulties. To test this question, we developed a web service + SMS/phone infrastructure ("Epharmix"). Utilization results were measured based on the total number of text messages or calls sent and received, with percentage engagement defined as a patient responding to a text message at least once in a given week, including the number of clinically significant alerts generated. User satisfaction surveys were sent once per month over the 18 months to measure satisfaction with the system, frequency and degree of communication. Descriptive statistics were used to describe the above information. In total, 28,386 text messages and 24,017 calls were sent to 929 patients over 9 months. Patients responded to 80% to 90% of messages allowing the system to detect 1164 clinically significant events. Patients reported increased satisfaction and communication with their provider. Epharmix increased the number of patient-provider interactions to over 10 on average in any given month for patients with diabetes, COPD, congestive heart failure, hypertension, surgical site infections, and breastfeeding difficulties. Engaging high-risk patients remains a difficult process that may be improved through novel, digital health interventions. The Epharmix platform enables increased patient engagement with very low risk to improve clinical outcomes. We demonstrated that engagement among high-risk populations is possible when health care comes conveniently to where they are.

27 July 2017 in JMIR Cardio
Verified
Journal Article
Open access
RPRobert Mattson Peters
Robert Mattson Peters
NSNishkala Shivakumar
Nishkala Shivakumar
RXRan Xu
Ran Xu
KJKavon Javaherian
Kavon Javaherian
ESEric Sink
Eric Sink
JBJonathan Byrd
Jonathan Byrd
Although hypertension (HTN) is a major modifiable risk factor for arterial damage, blood pressure (BP) remains poorly controlled in the hypertensive population. Telemedicine is a promising adjunct intervention that may complement traditional therapies and improve adherence rates; however, current approaches have multiple barriers to entry, including the use of relatively expensive Bluetooth devices or the dependence on smart phone utilization, which tend to exclude low-income and more elderly populations. The aim of this study was to design and implement a new phone call- and short message service text messaging-based intervention, Epharmix's EpxHypertension, in a quality improvement project that demonstrates the feasibility of this system for BP control in a family medicine setting. We recruited 174 patients from a community clinic in St Louis from a database of patients diagnosed with HTN. An automated call or text messaging system was used to monitor patient-reported BPs. If determined to be elevated, physicians were notified by an email, text, or electronic medical record alert. Mean systolic BPs (SBPs) and diastolic BPs (DBPs) were compared at the beginning and end of 12 weeks. After 12 weeks on the system, patients with a baseline SBP of 140 mm Hg or higher reduced SBP by 10.8 mm Hg (95% CI -14.5 to -7.2, P<.001) and DBP by 6.6 mm Hg (95% CI -9.9 to -3.4, P=.002), but no significant changes were observed in overall BPs and BPs in the group with baseline SBP less than 140 mm Hg. EpxHypertension provides a viable means to control HTN in patients with high baseline BPs despite previous therapy. This community implementation study demonstrates the feasibility of implementing EpxHypertension across a primary care setting without the need for smartphones or Bluetooth-linked BP cuffs. Future studies should evaluate its effectiveness in a randomized control trial compared with standard of care.